Appropriate Use Of Fdg Pet For The Management Of Cancer Patients

The use of PET (positron emission tomography) has become the standard quality of care for optimal management of patients with cancer. The availability of the hybrid PET/CT (positron emission tomography/computed tomography) scanner has further improved the utility of PET scanning and provides additional benefits to both patients and to the health system. This publication addresses the important issue of appropriateness of the application of PET/CT procedures in different clinical scenarios of many cancers. It is a useful resource for specialists in nuclear medicine and oncology, and aims to make reliable information widely available to those Member States where PET programmes are still in their planning phase or where the use of PET scanning is limited.

This book provides up-to-date guidance on the use of FDG PET to assess the biological activity and treatment response of a wide range of malignancies, including, for example, lung cancer, breast cancer, head and neck cancer, gastrointestinal cancer, and malignant lymphoma. In the era of precision medicine, numerous new anticancer agents, such as molecular targeted agents and immune checkpoint inhibitors, have been developed to improve outcomes in cancer patients. FDG PET plays a key role in evaluating the effects of these novel treatments because it can detect changes in the metabolic activity of tumors before any reduction in their size is visible on other imaging modalities. Accordingly, FDG PET is of prognostic as well as diagnostic value, and allows prompt changes in patient management. The book is written by expert clinicians from Japan, where the universal public health insurance system ensures that FDG PET is widely used in routine oncological practice and cancer screening. It represents an unrivaled and comprehensive resource that will be of value for all healthcare professionals in the field of clinical oncology.

While the use of positron emission tomography-computed tomography (PET-CT) is a standard of care in oncological practice in many developed countries, it is still limited in many low to middle income nations. To make reliable information more widely available, the IAEA convened an expert consultant group to review, based on the most recent developments of PET radiopharmaceuticals, Human Health Series No. 9, Appropriate Use of FDG-PET for the Management of Cancer Patients. This, the resulting publication, provides up to date recommendations on the optimal use of PET-CT imaging procedures in oncology. It is written for policy makers and decision makers who allocate resources dedicated to the health care system, a critical issue in the development of nuclear medicine in low and middle income countries. It will also benefit medical imaging practitioners as well as referring physicians.

This atlas is a superb guide to the use of PET-CT for the evaluation of treatment response in oncology patients based on its ability to assess tumor metabolic status. The first part of the book explains the role of PET-CT in response evaluation in different treatment settings. For comparison, overviews of the value and limitations of CT alone, PET alone, and anatomical and functional MRI are included. Guidance is also provided on the reporting of PET-CT scans in post-therapy scenarios. The second part of the book describes and illustrates the use of PET-CT with FDG and other tracers to assess the treatment response of malignancies at different anatomic sites. Featuring a wealth of images, informative case-based discussion, and evidence-based teaching points, these disease-specific chapters clearly demonstrate the key role that PET-CT can play in distinguishing early responders from patients who are non-responders or are resistant to treatment. Prompt and accurate evaluation of treatment response is vital as we enter the era of individualized medicine, and this atlas will persuade readers of the considerable advantages of PET-CT over conventional radiological and clinical methods.

Here is an exciting new guide to the use of PET-CT imaging in radiotherapy. You’ll get practical, useful information for utilizing this novel imaging technique—from different methods for contouring biological target volumes in various anatomic regions to how different experts use this imaging in targeted treatment. This thorough text helps you make concise, accurate treatment choices based on current evidence and expert authority. The result is an essential tool for everyone on the radiotherapy treatment team in the era of image-guided radiotherapy. Helps familiarize you with the basics of PET imaging in nuclear medicine. Covers the use of PET-CT with radiotherapy treatment planning, offering practical guidance in how different experts use this relatively new technology. Highlights contrast using full-color images, clearly indicating target volumes and different radiation dosages. Outlines the advantages and disadvantages of different techniques in contouring PET-CT target volumes for radiotherapy. Features case illustrations in using PET-CT in radiotherapy treatment planning for different tumor sites.

This concise, excellently illustrated pocket book provides an up-to-date summary of the science and practice of PET/CT imaging in lung cancer. The coverage encompasses the entire spectrum of lung cancer – pathology, radiological and PET/CT imaging, and management. Readers will also find information on the physics of PET and its use in respiratory gating and radiotherapy planning. The highlights of the book are the exquisite depiction of normal variants, pitfalls, and artifacts and a pictorial atlas of the various types of lung cancer and their manifestations. The contributing authors are well-known and experienced oncologists, pathologists, radiologists, and nuclear physicians. This book has been compiled under the auspices of the British Nuclear Medicine Society. It will be of high value for nuclear physicians, radiologists, referring clinicians and oncologists, and paramedical staff working in these fields

Over the past decade, PET-CT has achieved great success owing to its ability to simultaneously image structure and function, and show how the two are related. More recently, PET-MRI has also been developed, and it represents an exciting novel option that promises to have applications in oncology as well as neurology. The first part of this book discusses the basics of these dual-modality techniques, including the scanners themselves, radiotracers, scan performance, quantitation, and scan interpretation. As a result, the reader will learn how to perform the techniques to maximum benefit. The second part of the book then presents in detail the PET-CT and PET-MRI findings in cancers of the different body systems. The final two chapters address the use of PET/CT in radiotherapy planning and examine areas of controversy. The authors are world-renowned experts from North America, Europe, and Australia, and the lucid text is complemented by numerous high-quality illustrations.

FDG PET/CT has rapidly emerged as an invaluable combined imaging modality that provides both anatomic and functional information. This book, comprising a collection of images from oncology cases, is organized according to the role of FDG PET/CT in the evaluation and management of oncology patients, and only secondarily by organ or tumor entity. In this way, it reflects the issues that clinicians actually address, namely: identification of an unknown or unsuspected primary; determination of the extent of disease; evaluation of response to therapy; and surveillance after response, i.e., detection of recurrent disease. In total, 100 cases involving different primary tumors are presented to illustrate findings in these different circumstances. FDG PET/CT in Clinical Oncology will be of great value to all newcomers to this field, whether medical students, radiology, nuclear medicine, or oncology fellows, or practicing physicians.